🇺🇸 Eptifibatide Injection in United States

18 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 18

Most-reported reactions

1. Anaemia — 4 reports (22.22%)
2. Haemoglobin Decreased — 4 reports (22.22%)
3. Mediastinal Haematoma — 2 reports (11.11%)
4. Thrombocytopenia — 2 reports (11.11%)
5. Acute Kidney Injury — 1 report (5.56%)
6. Areflexia — 1 report (5.56%)
7. Circumstance Or Information Capable Of Leading To Medication Error — 1 report (5.56%)
8. Condition Aggravated — 1 report (5.56%)
9. Coronary Artery Thrombosis — 1 report (5.56%)
10. Disseminated Intravascular Coagulation — 1 report (5.56%)

Source database →

Frequently asked questions

Is Eptifibatide Injection approved in United States?

Eptifibatide Injection does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Eptifibatide Injection in United States?

Ministry of Science and Technology of the People´s Republic of China is the originator. The local marketing authorisation holder may differ — check the official source linked above.